On the public citation graph

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

0 signed · 362 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.25580openalex-snapshot
Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
inferredcites →https://doi.org/10.1002/cncr.9024openalex-snapshot
Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization
inferredcites →https://doi.org/10.1002/ijc.2910490504openalex-snapshot
Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer
inferredcites →https://doi.org/10.1002/path.1313openalex-snapshot
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres
inferredcites →https://doi.org/10.1002/path.2574openalex-snapshot
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis
inferredcites →https://doi.org/10.1002/path.2593openalex-snapshot
Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer
inferredcites →https://doi.org/10.1007/s10549-009-0539-2openalex-snapshot
Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
inferredcites →https://doi.org/10.1007/s10549-011-1744-3openalex-snapshot
Genetic heterogeneity in HER2 testing may influence therapy eligibility
inferredcites →https://doi.org/10.1007/s12094-011-0663-4openalex-snapshot
HER2 status in breast cancer: experience of a Spanish National Reference Centre
inferredcites →https://doi.org/10.1007/s12253-012-9518-8openalex-snapshot
Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer
inferredcites →https://doi.org/10.1016/0888-7543(89)90343-1openalex-snapshot
Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32
inferredcites →https://doi.org/10.1016/j.breast.2008.03.007openalex-snapshot
Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
inferredcites →https://doi.org/10.1016/j.ejca.2006.03.011openalex-snapshot
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis
inferredcites →https://doi.org/10.1016/j.ejca.2007.07.033openalex-snapshot
HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17
inferredcites →https://doi.org/10.1016/j.humpath.2010.04.023openalex-snapshot
Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer
inferredcites →https://doi.org/10.1016/j.prp.2011.05.008openalex-snapshot
Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer
inferredcites →https://doi.org/10.1016/j.tig.2006.06.007openalex-snapshot
Gene amplification in cancer
inferredcites →https://doi.org/10.1016/s0140-6736(07)60028-2openalex-snapshot
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(09)70063-4openalex-snapshot
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
inferredcites →https://doi.org/10.1016/s1470-2045(10)70119-4openalex-snapshot
Management of small HER2-positive breast cancers
inferredcites →https://doi.org/10.1016/s1470-2045(11)70234-0openalex-snapshot
Implications of rarity of chromosome 17 polysomy in breast cancer
inferredcites →https://doi.org/10.1016/s1525-1578(10)60467-9openalex-snapshot
Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
inferredcites →https://doi.org/10.1023/a:1021399923825openalex-snapshot
Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma
inferredcites →https://doi.org/10.1038/modpathol.2009.61openalex-snapshot
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
inferredcites →https://doi.org/10.1038/modpathol.2009.78openalex-snapshot
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
inferredcites →https://doi.org/10.1038/modpathol.2011.206openalex-snapshot
‘Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases
inferredcites →https://doi.org/10.1038/modpathol.2012.36openalex-snapshot
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
inferredcites →https://doi.org/10.1038/modpathol.3880505openalex-snapshot
Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status
inferredcites →https://doi.org/10.1038/sj.bjc.6690387openalex-snapshot
c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates
inferredcites →https://doi.org/10.1046/j.1524-4741.2001.21018.xopenalex-snapshot
Her-2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her-2/neu Polysomy
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1056/nejmoa052122openalex-snapshot
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa052306openalex-snapshot
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa053028openalex-snapshot
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1113205openalex-snapshot
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
inferredcites →https://doi.org/10.1089/gtmb.2011.0125openalex-snapshot
Evaluation of Genetic Status of HER-2/ neu and Aneusomy 17 by Fluorescence In Situ Hybridization and Comparison with Immunohistochemistry Assay from Indian Breast Cancer Patients
inferredcites →https://doi.org/10.1093/jnci/djq557openalex-snapshot
How Do You Tell Whether a Breast Cancer is HER2 Positive? Ongoing Studies Keep Debate in High Gear
inferredcites →https://doi.org/10.1093/jnci/djr490openalex-snapshot
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
inferredcites →https://doi.org/10.1097/01.pas.0000165528.78945.95openalex-snapshot
The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast
inferredcites →https://doi.org/10.1097/pdm.0b013e318064c72aopenalex-snapshot
Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast
inferredcites →https://doi.org/10.1111/j.1524-4741.2007.00396.xopenalex-snapshot
Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare Event
inferredcites →https://doi.org/10.1126/science.3798106openalex-snapshot
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
inferredcites →https://doi.org/10.1136/jclinpath-2011-200265openalex-snapshot
HER2 genetic heterogeneity in breast carcinoma
inferredcites →https://doi.org/10.1136/jcp.2006.043562openalex-snapshot
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
inferredcites →https://doi.org/10.1136/jcp.2007.050336openalex-snapshot
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
inferredcites →https://doi.org/10.1136/jcp.2011.089847openalex-snapshot
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods
inferredcites →https://doi.org/10.1158/0008-5472.sabcs10-pd10-01openalex-snapshot
Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience
inferredcites →https://doi.org/10.1158/0008-5472.sabcs11-p3-05-07openalex-snapshot
P3-05-07: Genetic Heterogeneity of Amplification Status in Breast Invasive Carcinoma with 2+ HER2 Immunostaining: What Can We Learn?
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2256openalex-snapshot
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1643openalex-snapshot
Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-06-0129openalex-snapshot
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
inferredcites →https://doi.org/10.1159/000329595openalex-snapshot
Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options
inferredcites →https://doi.org/10.1186/1471-2407-10-396openalex-snapshot
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
inferredcites →https://doi.org/10.1186/1746-1596-7-60openalex-snapshot
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections
inferredcites →https://doi.org/10.1186/bcr3208openalex-snapshot
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach
inferredcites →https://doi.org/10.1186/bcr996openalex-snapshot
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry
inferredcites →https://doi.org/10.1200/jco.1997.15.8.2894openalex-snapshot
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
inferredcites →https://doi.org/10.1200/jco.20.3.719openalex-snapshot
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2001.19.10.2714openalex-snapshot
Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
inferredcites →https://doi.org/10.1200/jco.2002.20.3.719openalex-snapshot
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2005.04.173openalex-snapshot
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.9584openalex-snapshot
Chromosome 17 polysomy and Her-2/neu status in metastatic breast cancer patients indicated to trastuzumab therapy
inferredcites →https://doi.org/10.1200/jco.2006.09.2775openalex-snapshot
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2007.11.6699openalex-snapshot
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
inferredcites →https://doi.org/10.1200/jco.2007.13.4296openalex-snapshot
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
inferredcites →https://doi.org/10.1200/jco.2007.14.8197openalex-snapshot
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.1009openalex-snapshot
CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
inferredcites →https://doi.org/10.1200/jco.2008.19.7939openalex-snapshot
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
inferredcites →https://doi.org/10.1200/jco.2011.35.2245openalex-snapshot
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2011.36.0107openalex-snapshot
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
inferredcites →https://doi.org/10.1309/9eym-6ve5-8f2y-cd9fopenalex-snapshot
Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus
inferredcites →https://doi.org/10.1309/ajcp09vutzwzxbmjopenalex-snapshot
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
inferredcites →https://doi.org/10.1309/ajcp0en6aqmwetzzopenalex-snapshot
HeterogeneousHER2Gene Amplification
inferredcites →https://doi.org/10.1309/ajcpatbz2jfn1qqcopenalex-snapshot
HER2Gene Amplification in Breast Cancer
inferredcites →https://doi.org/10.1309/ajcpsdg53beancyeopenalex-snapshot
Determination ofHER2Amplification by In Situ Hybridization
inferredcites →https://doi.org/10.1309/ajcpxtzskbrip07wopenalex-snapshot
Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations
inferredcites →https://doi.org/10.1309/fuqh-92b0-3902-5lhgopenalex-snapshot
Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay
inferredcites →https://doi.org/10.1309/j9vx-abug-kc4y-07dlopenalex-snapshot
Analysis of Intratumoral Heterogeneity and Amplification Status in Breast Carcinomas With Equivocal (2+) HER-2 Immunostaining
inferredcites →https://doi.org/10.1371/journal.pone.0040675openalex-snapshot
Fast and Non-Toxic In Situ Hybridization without Blocking of Repetitive Sequences
inferredcites →https://doi.org/10.1634/theoncologist.11-90001-34openalex-snapshot
HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy
inferredcites →https://doi.org/10.1634/theoncologist.2008-0230openalex-snapshot
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
inferredcites →https://doi.org/10.1634/theoncologist.2010-0035openalex-snapshot
Trastuzumab
inferredcites →https://doi.org/10.4103/0377-4929.85087openalex-snapshot
Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
inferredcites →https://doi.org/10.5858/133.4.611openalex-snapshot
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
inferredcites →https://doi.org/10.5858/134.2.162.aopenalex-snapshot
Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer.
inferredcites →https://doi.org/10.5858/134.2.162.bopenalex-snapshot
Is It Too Soon To Start Reporting HER2 Genetic Heterogeneity?
inferredcites →https://doi.org/10.5858/arpa.2011-0327-oaopenalex-snapshot
Centromere 17 Copy Number Alteration: Negative Prognostic Factor in Invasive Breast Cancer?

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4851024openalex-extracted
Comprehensive Review on Computational In-Situ Hybridization (Ish) Digital Pathology Using Image Analysis Techniques: Principles and Applications
inferred← citeshttps://doi.org/10.1002/1878-0261.12650openalex-snapshot
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
inferred← citeshttps://doi.org/10.1002/cam4.268openalex-snapshot
Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo‐adjuvant chemotherapy
inferred← citeshttps://doi.org/10.1002/cam4.3626openalex-snapshot
Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing
inferred← citeshttps://doi.org/10.1002/cncr.30460openalex-snapshot
Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study
inferred← citeshttps://doi.org/10.1002/cncr.30592openalex-snapshot
Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer
inferred← citeshttps://doi.org/10.1002/cpz1.942openalex-snapshot
Complementary Tumor Diagnosis by Single Cell–Based Cytogenetics Using Multi‐marker Fluorescence In Situ Hybridization (mFISH)
inferred← citeshttps://doi.org/10.1002/gcc.22337openalex-snapshot
Frequency of chromosome 17 polysomy in relation to CEP 17 copy number in a large breast cancer cohort
inferred← citeshttps://doi.org/10.1002/gcc.22504openalex-snapshot
Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study
inferred← citeshttps://doi.org/10.1002/ijc.29556openalex-snapshot
Topoisomerase‐1 gene copy aberrations are frequent in patients with breast cancer
inferred← citeshttps://doi.org/10.1002/path.4269openalex-snapshot
Biomarkers of drugs targeting HER ‐family signalling in cancer
inferred← citeshttps://doi.org/10.1007/7653_2014_23openalex-snapshot
Adapting HER2 Testing for a Different Organ: New Wine in Old Wineskins
inferred← citeshttps://doi.org/10.1007/978-1-4939-1578-1_14openalex-snapshot
Predictive Biomarkers in Breast Cancer: ER, PR and Her-2/neu
inferred← citeshttps://doi.org/10.1007/978-1-4939-3444-7_4openalex-snapshot
In Situ Hybridization of Breast Cancer Markers
inferred← citeshttps://doi.org/10.1007/978-3-030-16518-5_2openalex-snapshot
Invasive Ductal Carcinoma (NOS) of the Breast
inferred← citeshttps://doi.org/10.1007/978-3-030-83328-2_15openalex-snapshot
Predictive Biomarkers in Breast Cancer: ER, PR, and HER-2/NEU
inferred← citeshttps://doi.org/10.1007/978-3-031-20730-3_15openalex-snapshot
Multivariate Curve Resolution for Analysis of Heterogeneous System in Toxicogenomics
inferred← citeshttps://doi.org/10.1007/978-3-031-33602-7_10openalex-snapshot
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-35153-7_12openalex-snapshot
Pathology and Molecular Pathology of Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-981-10-6020-5_4openalex-snapshot
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-981-13-5877-7_15openalex-snapshot
Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast
inferred← citeshttps://doi.org/10.1007/s00428-015-1898-1openalex-snapshot
A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status
inferred← citeshttps://doi.org/10.1007/s00428-016-1903-3openalex-snapshot
Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment
inferred← citeshttps://doi.org/10.1007/s00428-016-1951-8openalex-snapshot
Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study
inferred← citeshttps://doi.org/10.1007/s00428-017-2189-9openalex-snapshot
Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization
inferred← citeshttps://doi.org/10.1007/s00428-017-2194-zopenalex-snapshot
Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis
inferred← citeshttps://doi.org/10.1007/s00428-018-2354-9openalex-snapshot
Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications
inferred← citeshttps://doi.org/10.1007/s00428-021-03036-2openalex-snapshot
Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1007/s00428-022-03267-xopenalex-snapshot
Updates on breast biomarkers
inferred← citeshttps://doi.org/10.1007/s00432-015-2009-zopenalex-snapshot
Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target
inferred← citeshttps://doi.org/10.1007/s00432-025-06105-0openalex-snapshot
Next-generation sequencing based deep learning model for prediction of HER2 status and response to HER2-targeted neoadjuvant chemotherapy
inferred← citeshttps://doi.org/10.1007/s00795-024-00386-zopenalex-snapshot
Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1007/s10120-014-0432-5openalex-snapshot
HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study
inferred← citeshttps://doi.org/10.1007/s10549-015-3522-0openalex-snapshot
Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number
inferred← citeshttps://doi.org/10.1007/s10549-016-3717-zopenalex-snapshot
HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
inferred← citeshttps://doi.org/10.1007/s10549-016-3856-2openalex-snapshot
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
inferred← citeshttps://doi.org/10.1007/s10549-016-4092-5openalex-snapshot
Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients
inferred← citeshttps://doi.org/10.1007/s10549-017-4453-8openalex-snapshot
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
inferred← citeshttps://doi.org/10.1007/s10549-017-4479-yopenalex-snapshot
Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines
inferred← citeshttps://doi.org/10.1007/s10549-018-4755-5openalex-snapshot
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
inferred← citeshttps://doi.org/10.1007/s10549-019-05148-5openalex-snapshot
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
inferred← citeshttps://doi.org/10.1007/s10555-022-10021-xopenalex-snapshot
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
inferred← citeshttps://doi.org/10.1007/s11427-025-3311-5openalex-snapshot
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
inferred← citeshttps://doi.org/10.1007/s12032-022-01817-6openalex-snapshot
The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
inferred← citeshttps://doi.org/10.1007/s12094-017-1800-5openalex-snapshot
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
inferred← citeshttps://doi.org/10.1007/s12253-014-9852-0openalex-snapshot
Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations
inferred← citeshttps://doi.org/10.1007/s12253-016-0091-4openalex-snapshot
Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12282-014-0566-7openalex-snapshot
Pathological examination of breast cancer biomarkers: current status in Japan
inferred← citeshttps://doi.org/10.1007/s12282-020-01208-7openalex-snapshot
ER staining levels affect HER2 staining and heterogeneity
inferred← citeshttps://doi.org/10.1007/s12282-022-01330-8openalex-snapshot
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
inferred← citeshttps://doi.org/10.1007/s13193-023-01829-2openalex-snapshot
Atypical Co-amplification with Co-localization of HER2 Gene in Breast Cancer: Combined IHC/FISH Approach as per ASCO/CAP 2018 Guidelines for Targeted Therapy Eligibility
inferred← citeshttps://doi.org/10.1016/b978-0-12-800886-7.00021-2openalex-snapshot
Molecular Testing in Breast Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-822824-1.00030-4openalex-snapshot
Molecular testing in breast cancer
inferred← citeshttps://doi.org/10.1016/j.anndiagpath.2015.08.001openalex-snapshot
Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks
inferred← citeshttps://doi.org/10.1016/j.anndiagpath.2020.151576openalex-snapshot
Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes
inferred← citeshttps://doi.org/10.1016/j.annpat.2014.08.018openalex-snapshot
Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
inferred← citeshttps://doi.org/10.1016/j.annpat.2021.07.014openalex-snapshot
Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France
inferred← citeshttps://doi.org/10.1016/j.breast.2014.12.006openalex-snapshot
Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2022.02.002openalex-snapshot
HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2014.11.009openalex-snapshot
Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy
inferred← citeshttps://doi.org/10.1016/j.clbc.2016.02.016openalex-snapshot
Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2017.11.016openalex-snapshot
Evaluation of Discordance in Primary Tumor and Lymph Node Response After Neoadjuvant Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clcc.2019.05.001openalex-snapshot
Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA
inferred← citeshttps://doi.org/10.1016/j.compbiolchem.2026.109391openalex-snapshot
Construction of efficacy prediction model for T-DXd treatment of HER2-positive and HER2-low expression breast cancer based on hematological indicators: A real-world study
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102286openalex-snapshot
Targeting HER2 heterogeneity in breast cancer
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2016.09.002openalex-snapshot
Systemic therapy for HER2-positive early-stage breast cancer
inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.07.075openalex-snapshot
Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies
inferred← citeshttps://doi.org/10.1016/j.gene.2016.12.027openalex-snapshot
Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2013.11.016openalex-snapshot
HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2016.12.004openalex-snapshot
Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype
inferred← citeshttps://doi.org/10.1016/j.humpath.2017.02.004openalex-snapshot
Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2017.04.016openalex-snapshot
Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients
inferred← citeshttps://doi.org/10.1016/j.humpath.2019.04.002openalex-snapshot
MDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.humpath.2020.01.003openalex-snapshot
The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups
inferred← citeshttps://doi.org/10.1016/j.humpath.2020.08.006openalex-snapshot
Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2022.05.011openalex-snapshot
Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity
inferred← citeshttps://doi.org/10.1016/j.jasc.2017.09.003openalex-snapshot
HER2 FISH concordance in breast cancer patients with both cytology and surgical pathology specimens
inferred← citeshttps://doi.org/10.1016/j.jmoldx.2016.09.010openalex-snapshot
Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status
inferred← citeshttps://doi.org/10.1016/j.jncc.2024.12.008openalex-snapshot
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
inferred← citeshttps://doi.org/10.1016/j.jpi.2022.100116openalex-snapshot
Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer
inferred← citeshttps://doi.org/10.1016/j.labinv.2025.104240openalex-snapshot
Analysis of Human Epidermal Growth Factor Receptor 2 (HER2) Heterogeneity at the Protein and Gene Levels in Endometrial Cancer: Refining HER2 Reporting and HER2-Directed Therapies
inferred← citeshttps://doi.org/10.1016/j.mee.2017.10.007openalex-snapshot
Microfluidic-assisted chromogenic in situ hybridization (MA-CISH) for fast and accurate breast cancer diagnosis
inferred← citeshttps://doi.org/10.1016/j.modpat.2025.100785openalex-snapshot
Not All HER2-Positive Breast Cancers Are the Same: Intratumoral Heterogeneity, Low-Level HER2 Amplification, and Their Impact on Neoadjuvant Therapy Response
inferred← citeshttps://doi.org/10.1016/j.mpdhp.2014.10.002openalex-snapshot
ER, PR and HER2 testing in breast cancer
inferred← citeshttps://doi.org/10.1016/j.mpdhp.2019.10.014openalex-snapshot
The assessment of HER2 status and its clinical implication in breast cancer
inferred← citeshttps://doi.org/10.1016/j.mpdhp.2023.11.001openalex-snapshot
Invasive breast cancer reporting guidelines: ICCR, CAP, RCPath, RCPA datasets and future directions
inferred← citeshttps://doi.org/10.1016/j.mri.2025.110429openalex-snapshot
MRI-based habitat analysis for Intratumoral heterogeneity quantification combined with deep learning for HER2 status prediction in breast cancer
inferred← citeshttps://doi.org/10.1016/j.nano.2016.02.014openalex-snapshot
Quantum dot nanoparticle for optimization of breast cancer diagnostics and therapy in a clinical setting
inferred← citeshttps://doi.org/10.1016/j.path.2017.09.006openalex-snapshot
Ancillary Prognostic and Predictive Testing in Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.pathol.2017.05.009openalex-snapshot
HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program
inferred← citeshttps://doi.org/10.1016/j.patol.2017.12.002openalex-snapshot
Consenso de la Sociedad Española de Anatomía Patológica y la Sociedad Española de Oncología Médica sobre biomarcadores en cáncer de mama
inferred← citeshttps://doi.org/10.1016/j.preme.2024.100006openalex-snapshot
Intratumor heterogeneity in breast cancer: Tracing its origins and translating findings into clinical practice
inferred← citeshttps://doi.org/10.1016/j.prp.2016.09.014openalex-snapshot
Utility of cytopathological specimens and an automated image analysis for the evaluation of HER2 status and intratumor heterogeneity in breast carcinoma
inferred← citeshttps://doi.org/10.1016/j.prp.2018.10.015openalex-snapshot
Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer
inferred← citeshttps://doi.org/10.1016/j.prp.2022.154258openalex-snapshot
The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.reactfunctpolym.2017.10.025openalex-snapshot
Evaluation of molecularly imprinted polymer based on HER2 epitope for targeted drug delivery in ovarian cancer mouse model
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.02.016openalex-snapshot
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
inferred← citeshttps://doi.org/10.1016/j.trecan.2023.11.001openalex-snapshot
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
inferred← citeshttps://doi.org/10.1021/acs.analchem.6c01012openalex-snapshot
Multiplexed Peptide-Based Fluorescent Probe Platform for Analysis of HER2-Positive Exosomal Membrane Proteins
inferred← citeshttps://doi.org/10.1038/bjc.2014.483openalex-snapshot
HER2/neu testing in primary colorectal carcinoma
inferred← citeshttps://doi.org/10.1038/labinvest.2016.121openalex-snapshot
Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer
inferred← citeshttps://doi.org/10.1038/labinvest.2017.93openalex-snapshot
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence
inferred← citeshttps://doi.org/10.1038/modpathol.2015.112openalex-snapshot
Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data
inferred← citeshttps://doi.org/10.1038/modpathol.2016.175openalex-snapshot
‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study
inferred← citeshttps://doi.org/10.1038/nrclinonc.2013.230openalex-snapshot
Updated guideline recommendations for HER2 testing
inferred← citeshttps://doi.org/10.1038/nrclinonc.2016.1openalex-snapshot
Biomarkers of residual disease after neoadjuvant therapy for breast cancer
inferred← citeshttps://doi.org/10.1038/s41374-018-0172-yopenalex-snapshot
High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer
inferred← citeshttps://doi.org/10.1038/s41379-018-0023-9openalex-snapshot
Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility
inferred← citeshttps://doi.org/10.1038/s41379-020-00695-5openalex-snapshot
Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays
inferred← citeshttps://doi.org/10.1038/s41379-020-00728-zopenalex-snapshot
Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents
inferred← citeshttps://doi.org/10.1038/s41379-020-0519-yopenalex-snapshot
A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell
inferred← citeshttps://doi.org/10.1038/s41379-021-00813-xopenalex-snapshot
HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity
inferred← citeshttps://doi.org/10.1038/s41416-023-02287-xopenalex-snapshot
Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
inferred← citeshttps://doi.org/10.1038/s41523-023-00605-3openalex-snapshot
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
inferred← citeshttps://doi.org/10.1038/s41571-023-00849-9openalex-snapshot
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
inferred← citeshttps://doi.org/10.1038/s41598-017-07176-xopenalex-snapshot
Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
inferred← citeshttps://doi.org/10.1038/s41598-019-48212-2openalex-snapshot
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
inferred← citeshttps://doi.org/10.1038/s41598-019-54471-wopenalex-snapshot
Centromere 17 copy number gain reflects chromosomal instability in breast cancer
inferred← citeshttps://doi.org/10.1038/s41598-023-36811-zopenalex-snapshot
Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images
inferred← citeshttps://doi.org/10.1038/s41698-021-00224-wopenalex-snapshot
Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses
inferred← citeshttps://doi.org/10.1038/srep20277openalex-snapshot
Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
inferred← citeshttps://doi.org/10.1039/c5lc00816fopenalex-snapshot
Microfluidic device for DNA amplification of single cancer cells isolated from whole blood by self-seeding microwells
inferred← citeshttps://doi.org/10.1053/j.semdp.2015.02.011openalex-snapshot
Predictive markers in breast cancer: An update on ER and HER2 testing and reporting
inferred← citeshttps://doi.org/10.1055/s-0042-1751052openalex-snapshot
Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
inferred← citeshttps://doi.org/10.1063/1.4940274openalex-snapshot
Medical image segmentation to estimate HER2 gene status in breast cancer
inferred← citeshttps://doi.org/10.1080/01478885.2015.1115587openalex-snapshot
Comparison of immunohistochemistry within situhybridization methods: discrepancy resolution and implications for low-mid income countries
inferred← citeshttps://doi.org/10.1080/10520295.2017.1290276openalex-snapshot
Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward “precision” cancer therapy
inferred← citeshttps://doi.org/10.1093/ajcp/aqab042openalex-snapshot
Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results
inferred← citeshttps://doi.org/10.1093/ajcp/aqab117openalex-snapshot
HER2-Low Breast Cancers
inferred← citeshttps://doi.org/10.1093/ajcp/aqaf006openalex-snapshot
HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry
inferred← citeshttps://doi.org/10.1093/ajcp/aqv018openalex-snapshot
Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis
inferred← citeshttps://doi.org/10.1093/ajcp/aqw017openalex-snapshot
Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma
inferred← citeshttps://doi.org/10.1093/ajcp/aqw130openalex-snapshot
Genomic Copy Number Analysis ofHER2-Equivocal Breast Cancers
inferred← citeshttps://doi.org/10.1093/ajcp/aqw224openalex-snapshot
Her2/neu Status Determination in Breast Cancer
inferred← citeshttps://doi.org/10.1093/ajcp/aqx016openalex-snapshot
Breast Tumor Resembling Tall Cell Variant of Papillary Thyroid Carcinoma
inferred← citeshttps://doi.org/10.1093/ajcp/aqy136openalex-snapshot
Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy
inferred← citeshttps://doi.org/10.1093/ajcp/aqz010openalex-snapshot
Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity
inferred← citeshttps://doi.org/10.1097/jcma.0000000000000883openalex-snapshot
Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy
inferred← citeshttps://doi.org/10.1097/md.0000000000000645openalex-snapshot
HER2 Status Determination
inferred← citeshttps://doi.org/10.1097/pai.0000000000000047openalex-snapshot
HER2 Immunohistochemical Assessment With A0485 Polyclonal Antibody
inferred← citeshttps://doi.org/10.1097/pai.0000000000000136openalex-snapshot
HER2 Genetic Heterogeneity in Gastric Cancer
inferred← citeshttps://doi.org/10.1097/pai.0000000000000304openalex-snapshot
Comparison of Dual-ISH (DISH) With Fluorescence In Situ Hybridization (FISH) and Correlation With Immunohistochemical Findings for HER2/Neu Status in Breast Carcinoma
inferred← citeshttps://doi.org/10.1097/pai.0000000000000646openalex-snapshot
Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma
inferred← citeshttps://doi.org/10.1097/pai.0000000000000773openalex-snapshot
Chromogenic and Silver in Situ Hybridization for Identification of HER 2 Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1097/pap.0000000000000074openalex-snapshot
Tumor Heterogeneity in Breast Cancer
inferred← citeshttps://doi.org/10.1097/pas.0000000000000268openalex-snapshot
Assessing the HER2 Status in Mucinous Epithelial Ovarian Cancer on the Basis of the 2013 ASCO/CAP Guideline Update
inferred← citeshttps://doi.org/10.1097/pas.0000000000000375openalex-snapshot
Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System
inferred← citeshttps://doi.org/10.1097/pas.0000000000001106openalex-snapshot
Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe
inferred← citeshttps://doi.org/10.1097/pat.0000000000000326openalex-snapshot
Predicting discordant HER2 results in ipsilateral synchronous invasive breast carcinomas: experience from a single institution
inferred← citeshttps://doi.org/10.1109/rbme.2024.3357877openalex-snapshot
Deep Learning in Breast Cancer Imaging: A Decade of Progress and Future Directions
inferred← citeshttps://doi.org/10.1109/siu.2017.7960428openalex-snapshot
Automatically diagnosing HER2 amplification status for breast cancer patients using large FISH images
inferred← citeshttps://doi.org/10.1111/apm.12518openalex-snapshot
Validity of immunohistochemistry method in predicting HER‐2 gene status and association of clinicopathological variables with it in invasive breast cancer patients
inferred← citeshttps://doi.org/10.1111/cas.12886openalex-snapshot
Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH , and dual‐color in situ hybridization
inferred← citeshttps://doi.org/10.1111/his.12357openalex-snapshot
The updated ASCO / CAP guideline recommendations for HER 2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice
inferred← citeshttps://doi.org/10.1111/his.12723openalex-snapshot
Impact of the 2013 A merican S ociety of C linical O ncology/ C ollege of A merican P athologists guideline recommendations for human epidermal growth factor receptor 2 ( HER 2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HER 2 gene amplification by…
inferred← citeshttps://doi.org/10.1111/his.12974openalex-snapshot
The FlexISH assay brings flexibility to cytogenetic HER2 testing
inferred← citeshttps://doi.org/10.1111/his.13010openalex-snapshot
HER2 gene copy number and breast cancer‐specific survival
inferred← citeshttps://doi.org/10.1111/his.13208openalex-snapshot
Counting invasive breast cancer cells in the HER2 silver in‐situ hybridization test: how many cells are enough?
inferred← citeshttps://doi.org/10.1111/his.13253openalex-snapshot
HER 2 FISH results in breast cancers with increased CEN 17 signals using alternative chromosome 17 probes – reclassifying cases in the equivocal category
inferred← citeshttps://doi.org/10.1111/his.13704openalex-snapshot
HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and within‐situhybridisation
inferred← citeshttps://doi.org/10.1111/his.14728openalex-snapshot
The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer
inferred← citeshttps://doi.org/10.1111/his.14770openalex-snapshot
Novel markers in breast pathology
inferred← citeshttps://doi.org/10.1111/his.15000openalex-snapshot
Improved concordance of challenging human epidermal growth factor receptor 2 dual in‐situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer
inferred← citeshttps://doi.org/10.1111/his.15213openalex-snapshot
Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
inferred← citeshttps://doi.org/10.1111/pin.12407openalex-snapshot
The assessment of HER2 status in breast cancer: the past, the present, and the future
inferred← citeshttps://doi.org/10.1136/jclinpath-2014-202571openalex-snapshot
Updated UK Recommendations for HER2 assessment in breast cancer
inferred← citeshttps://doi.org/10.1136/jclinpath-2019-205830openalex-snapshot
Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2
inferred← citeshttps://doi.org/10.1136/jclinpath-2020-207097openalex-snapshot
Significance of adenosquamous proliferation in breast lesions
inferred← citeshttps://doi.org/10.1136/jcp-2022-208632openalex-snapshot
UK recommendations for HER2 assessment in breast cancer: an update
inferred← citeshttps://doi.org/10.1148/rg.220103openalex-snapshot
Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy
inferred← citeshttps://doi.org/10.1155/2017/2321916openalex-snapshot
Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue
inferred← citeshttps://doi.org/10.1155/2021/6684629openalex-snapshot
HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-14-0491openalex-snapshot
89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-15-0561openalex-snapshot
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-25-1923openalex-snapshot
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
inferred← citeshttps://doi.org/10.1158/2159-8290.c.6548945openalex-snapshot
Data from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
inferred← citeshttps://doi.org/10.1158/2159-8290.c.6548945.v1openalex-snapshot
Data from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-20-1557openalex-snapshot
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
inferred← citeshttps://doi.org/10.1159/000512283openalex-snapshot
Biomarkers in Her2- Positive Disease
inferred← citeshttps://doi.org/10.1177/1066896920911421openalex-snapshot
Isolated CEP17 Copy Number Gain in Invasive Breast Cancer Results in a “Reverse” Amplification Status
inferred← citeshttps://doi.org/10.1177/1534735420983463openalex-snapshot
San Huang Decoction Targets Aurora Kinase A to Inhibit Tumor Angiogenesis in Breast Cancer
inferred← citeshttps://doi.org/10.1177/17588359251367344openalex-snapshot
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)
inferred← citeshttps://doi.org/10.1186/s12885-016-3001-yopenalex-snapshot
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1186/s12885-020-07114-7openalex-snapshot
Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review
inferred← citeshttps://doi.org/10.1186/s12935-022-02761-1openalex-snapshot
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
inferred← citeshttps://doi.org/10.1186/s12957-017-1255-8openalex-snapshot
Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1186/s12957-021-02387-zopenalex-snapshot
Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment
inferred← citeshttps://doi.org/10.1186/s13000-016-0537-8openalex-snapshot
Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection
inferred← citeshttps://doi.org/10.1186/s13000-024-01455-8openalex-snapshot
Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer
inferred← citeshttps://doi.org/10.1186/s13000-024-01508-yopenalex-snapshot
Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1186/s13000-024-01588-wopenalex-snapshot
Interlaboratory variability of HER2 fluorescence in situ hybridization testing in breast cancer: results of a multicenter proficiency-testing ring study in China
inferred← citeshttps://doi.org/10.1186/s13058-015-0561-8openalex-snapshot
Quantification of HER family receptors in breast cancer
inferred← citeshttps://doi.org/10.1186/s13059-015-0657-6openalex-snapshot
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
inferred← citeshttps://doi.org/10.1186/s40364-024-00565-1openalex-snapshot
HER2-targeted therapies in cancer: a systematic review
inferred← citeshttps://doi.org/10.1186/s42047-026-00266-zopenalex-snapshot
An audit of Her2/neu FISH signal patterns in immunohistochemically equivocal breast carcinomas from a tertiary cancer centre in India
inferred← citeshttps://doi.org/10.1188/20.cjon.635-643openalex-snapshot
Molecular Biomarkers: A Review of Multiple Applications in Clinical Care of Colorectal Cancer
inferred← citeshttps://doi.org/10.1200/jco.2013.50.9984openalex-snapshot
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
inferred← citeshttps://doi.org/10.1200/jco.2018.77.8738openalex-snapshot
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
inferred← citeshttps://doi.org/10.1200/jgo.2016.006072openalex-snapshot
Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
inferred← citeshttps://doi.org/10.1309/ajcp3q9wfoqtkuvvopenalex-snapshot
The New Equivocal
showing the first 200 of 275 · page through all 275
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.